Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes
Source : https://pubmed.ncbi.nlm.nih.gov/38870570/
The detection of germline pathogenic variants (gPVs) in BRCA1/2 and other breast cancer (BC) genes is rising exponentially thanks to the advent of multi-gene panel testing. This promising technology, coupled...
The rise of multi-gene panel testing for breast cancer enhances detection and treatment options but introduces complexities with variants of uncertain significance, highlighting the need for updated clinical guidelines.
Lipid profile in breast cancer: From signaling pathways to treatment strategies
Source : https://pubmed.ncbi.nlm.nih.gov/37993054/
Breast cancer is the most prevalent cancer in women. Metabolic abnormalities, particularly increased lipid synthesis and uptake, impact the onset and progression of the disease. However, the influence of lipid...
Lipid metabolism in breast cancer differs by subtype and hormone status, influencing tumor progression and drug resistance, particularly through fatty acid synthesis and membrane composition.
New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy
Source : https://pubmed.ncbi.nlm.nih.gov/38576614/
Oncolytic virus (OV) therapy has emerged as a promising frontier in cancer treatment, especially for solid tumours. While immunotherapies like immune checkpoint inhibitors and CAR-T cells have demonstrated impressive results,...
Oncolytic viruses (OVs) show potential in breast cancer therapy, especially when combined with other treatments, improving outcomes despite current challenges in monotherapy efficacy and safety.
LCN2: Versatile players in breast cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38171248/
Lipocalin 2 (LCN2) is a secreted glycoprotein that is produced by immune cells, including neutrophils and macrophages. It serves various functions such as transporting hydrophobic ligands across the cellular membrane,...
Lipocalin 2 (LCN2) is critical in breast cancer progression, influencing cell proliferation, apoptosis, and resistance to therapy, making it a promising target for future therapeutic strategies.
HER2-Low Breast Cancer: Now and in the Future
Source : https://pubmed.ncbi.nlm.nih.gov/38291745/
Breast cancer is a heterogeneous disease, and its subtypes are characterized by hormone receptor and human epidermal growth factor receptor 2 (HER2) expression status. "HER2-low" tumors, which exhibit a low...
HER2-low breast cancer, previously deemed untreatable with anti-HER2 agents, shows promising responses to new therapies like trastuzumab-deruxtecan, emphasizing the need for further biological and prognostic research.